The future of contamination control in pharma: from compliance to innovation
This webinar explores the benefits of accelerated microbial identification using MALDI-TOF in pharmaceutical contamination control strategies.
Microbiology laboratories’ key role in pharmaceutical manufacturing requires effective contamination control strategies and, increasingly, greater use of new technology as pharma companies pursue speed, but never at the cost of quality.
Contamination Control Strategies (CCS) offer a comprehensive, risk-based framework to prevent, detect and manage contamination in pharmaceutical environments. Mandated by regulatory bodies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) – and guided by organisations like the Parenteral Drug Association (PDA) , CCS plays a critical role in ensuring product integrity.